Advanced Prostate Cancer Consensus Conference OncoAlert PCF Science silke gillessen #APCCC24 Advanced Prostate Cancer Consensus Conference 👉 majority of panelists favored retreating pts with mCRPC #prostatecancer with lutetium-177 RLT Rx if they had response to previous Lutetium-177 Rx lasting for more than 6 months OncoAlert PCF Science

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Excellent talk by Heather H. Cheng on who should undergo germ line testing?👉ongoing neoadjuvant trials in germline mutation+ #prostatecancer and take home message👇OncoAlert PCF Science silke gillessen

💫🌟👏👏👏🌟💫

Also available as an audio podcast in all the usual places, just search GU Cast or Uromigos or Oncoalert. And please subscribe/follow/like and rate all of us!

It's HERE‼️
Uromigos , GU Cast | Urology podcast! & OncoAlert 🚨
LIVE AT #APCCC24
Listen to us Jam and get ready to smile 🙂

💫🌟Key insights from Dr. Ana Aparicio at #APCCC24 :
#APCCC24
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin

🧬 Understanding non-DDR genomic alterations is crucial in prostate cancer management.
💊 Patients with MSI high, TMB high, MMR deficient cancers may benefit from PD1…

💫🌟Navigating PSMA PET for optimal patient selection in radioligand therapy with insights from Thomas A. Hope at #APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
📈 Uptake should be greater than the liver on PSMA PET for selecting PSMA RLT candidates.
🚫 Avoid using…

💫🌟At #APCCC24 , Dr. Heather H. Cheng shares her approach to germline testing in prostate cancer:
#APCCC24
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
👨‍👩‍👧‍👦 Always start with a thorough family history.
🧬 Recommend germline testing for high-risk localized, N+, and metastatic…

💫🌟Dr. Louise Emmett at #APCCC24 illuminates the balance needed in radioligand therapy dosing:🌟💫
#APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🚩 Marrow toxicity is common; severe cases often signal disease progression.
🔬 Biomarkers are crucial in guiding…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 How to monitor and manage toxicities with Lutetium-177 PSMA RLT? #LuisEmmett 👉adaptive dosing based on SPECT scan results may improve toxicity, & rule out disease progression before assuming marrow toxicity👇OncoAlert PCF Science

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 brilliant talk by Michael Hofman 👉Current gallium and fluorinated PSMA diagnostic tracers are equivalent & current PSMA radiologist therapies (PSMA-617 & PSMA I&T)seem radio-equivalent👇OncoAlert PCF Science silke gillessen

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 majority of panelist favor offering Lutetium-177 RLT Rx after ARPI and docetaxel Rx in mCRPC #prostatecancer 👇 OncoAlert PCF Science

💫🌟At #APCCC24 , the debate continues on the optimal number of 177Lu-PSMA therapy cycles:
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🔄 For patients responding after 4 cycles:
   - Majority vote to continue to 6 cycles: 📊 Yes: 43%, Selectively: 39%
🚫 If no significant…

💫🌟Monitoring response during 177Lu-PSMA therapy is a hot topic at #APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🎯 70% recommend imaging for all patients to track therapy response.
🔍 22% opt for imaging only in selected cases.
✅ Ensuring timely adjustments and…

💫🌟The consensus on imaging for 177Lu-PSMA therapy is clear at #APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🔬 PSMA PET/CT remains the cornerstone of eligibility evaluation.
🔄 A significant preference for adding FDG PET selectively for ambiguous cases.
🦴 Bone…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Ana Aparicio ‘s excellent perspective on how to interpret clinical genomic tests👇 and framework for drug development in advanced #prostatecancer & highlights ongoing SWOG Cancer Research Network 2312 trial OncoAlert PCF Science

💫🌟Navigating the world of PSMA diagnostics at #APCCC24 with Michael S. Hofman:
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🎯 The best PSMA radiotracer? The one you can access!
🔄 68Ga-PSMA-11 & 18F-DCFPyL showing equivalent promise.
🆕 18F-PSMArh7: Freshly FDA-approved…

💫🌟Navigating PSMA PET for optimal patient selection in radioligand therapy with insights from Thomas A. Hope at #APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
📈 Uptake should be greater than the liver on PSMA PET for selecting PSMA RLT candidates.
🚫 Avoid using…

💫🌟Dr. Louise Emmett at #APCCC24 illuminates the balance needed in radioligand therapy dosing:🌟💫
#APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🚩 Marrow toxicity is common; severe cases often signal disease progression.
🔬 Biomarkers are crucial in guiding…

💫🌟At #APCCC24 , Dr. Matthew R. Smith reveals key insights on PSMA radioligand therapy in prostate cancer treatment:
#APCCC24 :🌟💫
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🔄 Optimal chemo & PSMA RLT sequence is still being explored.
🔎 Studies show 177Lu-PSMA-617 may…